Vincent OssipowPartner at Omega Funds
Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a Partner for private investments, prior to it he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund. He was before a research fellow at the University of Geneva, studying neuroscience, and trained as a postdoctoral fellow at the National Cancer Institute in Bethesda, MD. He completed a CFA training (CFA Institute), a certificate in International Finance and Global Markets at the Georgetown University School of Business and holds an MS in Computational Sciences, an MS in Molecular Biology, and a PhD in Molecular Biology, all from the University of Geneva. Current board of Directors positions comprise, Immunic (Germany, Nasdaq-listed), Bioinvent (Sweden, Nasdaq OMX-listed), Sophia Genetics (Switzerland, private), Etherna Immuno-Oncology (Belgium, private), Andrew Alliance (Switzerland, private), ForX (Switzerland, private). Prior Board positions comprise, RainDance technologies (US, acquired), LifeSpan (US, acquired), Endosense (Switzerland, acquired), Kuros (Switzerland, public).